When was Bedaquilin launched in China?

Bedaquiline (Bedaquiline) was launched in China on January 1, 2020. At present, bedaquiline has been included in the domestic Class B medical insurance reimbursement drugs, Bedaquiline is an anti-tuberculosis drug produced by Johnson & Johnson. Bedaquiline is a diarylquinoline anti-mycobacterial drug used to treat patients with multi-drug-resistant tuberculosis(MDR-TB) Adult and pediatric patients(5 years old and above, weighing at least15 kg)combination therapy, reservebedaquiline for use when an effective treatment option is not available.

If a dose is missed during the first 2 weeks of treatment, do not take the missed dose (Skip the dose and continue the daily dosing schedule). Starting from the 3 week, if you miss a dose of medication, you should take the missed dose as soon as possible and then resume the dosing regimen of 3 times a week. The total dose of bedaquilineover a 7 day period should not exceed the recommended weekly dose(with at least 24 hours ) between each dose. Do not use bedaquilinetreatment if there is latent infection due to Mycobacterium tuberculosis, drug-susceptible tuberculosis, extrapulmonary tuberculosis, infections caused by non-tuberculous mycobacteria. Bedaquiline is metabolized by CYP3A4 and therefore its systemic exposure and therapeutic efficacy may be reduced when coadministered with CYP3A4 inducers. During bedaquiline treatment, avoid coadministration of strong CYP3A4 inducers, such as rifamycins (i.e., rifampicin, rifapentine, and rifabutin), or moderate CYP3A4 inducers.

The Russian version is consistent with the domestic imported drug manufacturers, and the price in Russian hospitals100mg188 tablets1About four or five thousand. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0